Uzbekistan and Egypt will jointly launch the production of a medicine for hepatitis C, Dunyo Information Agency reported.

According to the report, an online meeting was held between representatives of the Agency for the Development of the Pharmaceutical Industry of Uzbekistan and Egyptian companies ACDIMA and Dentafill Plus. The discussions focused on expanding cooperation between Uzbekistan and Egypt in the pharmaceutical sector, including the transfer of modern drug manufacturing technologies and their localization in Uzbekistan. 

As noted, the parties agreed, as the first stage of cooperation, to begin production of Daclatasvir and Sofosbuvir for the Uzbek market to treat the hepatitis C virus. The project provides for the gradual transfer of production technologies to Uzbekistan, the involvement of Egyptian specialists, training of local personnel, and the adaptation of production capacities.

In addition, the meeting explored opportunities for the localization of more than 1,000 types of medicines, as well as prospects for establishing insulin production in Uzbekistan.

It was emphasized that the cooperation will contribute to the development of the national pharmaceutical industry, reduce dependence on imports, and further strengthen industrial cooperation between the two countries.

“Projects of this nature are an important step toward ensuring the population’s access to high-quality and affordable medicines and toward transforming Uzbekistan into are gional pharmaceutical hub,” the report said.